HCP, Inc. (NYSE:HCP) COO Thomas Klaritch sold 82,532 shares of the company’s stock in a transaction dated Tuesday, December 4th. The stock was sold at an average price of $29.51, for a total transaction of $2,435,519.32. Following the transaction, the chief operating officer now owns 256,280 shares of the company’s stock, valued at approximately $7,562,822.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
NYSE HCP traded down $0.26 during trading hours on Friday, hitting $29.97. 918,251 shares of the company’s stock traded hands, compared to its average volume of 3,369,227. HCP, Inc. has a 52-week low of $21.48 and a 52-week high of $30.26. The stock has a market cap of $13.67 billion, a PE ratio of 15.37, a P/E/G ratio of 7.33 and a beta of 0.23. The company has a current ratio of 0.48, a quick ratio of 0.48 and a debt-to-equity ratio of 1.21.
HCP (NYSE:HCP) last announced its quarterly earnings data on Wednesday, October 31st. The real estate investment trust reported $0.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.10. HCP had a net margin of 9.16% and a return on equity of 3.06%. The company had revenue of $456.00 million during the quarter, compared to analysts’ expectations of $456.59 million. During the same quarter in the prior year, the company earned $0.48 EPS. HCP’s revenue was up .4% compared to the same quarter last year. On average, sell-side analysts forecast that HCP, Inc. will post 1.82 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, November 20th. Investors of record on Monday, November 5th were paid a dividend of $0.37 per share. The ex-dividend date of this dividend was Friday, November 2nd. This represents a $1.48 annualized dividend and a yield of 4.94%. HCP’s dividend payout ratio is presently 75.90%.
A number of hedge funds and other institutional investors have recently made changes to their positions in HCP. Carnegie Capital Asset Management LLC grew its stake in shares of HCP by 29.7% in the 3rd quarter. Carnegie Capital Asset Management LLC now owns 10,925 shares of the real estate investment trust’s stock valued at $317,000 after buying an additional 2,500 shares during the period. Vanguard Group Inc. grew its stake in shares of HCP by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 75,247,949 shares of the real estate investment trust’s stock valued at $1,980,527,000 after buying an additional 196,049 shares during the period. Legal & General Group Plc grew its stake in shares of HCP by 1.2% in the 3rd quarter. Legal & General Group Plc now owns 3,690,653 shares of the real estate investment trust’s stock valued at $97,108,000 after buying an additional 44,998 shares during the period. Standard Life Aberdeen plc grew its stake in shares of HCP by 3.3% in the 3rd quarter. Standard Life Aberdeen plc now owns 249,259 shares of the real estate investment trust’s stock valued at $6,562,000 after buying an additional 7,990 shares during the period. Finally, Rehmann Capital Advisory Group grew its stake in shares of HCP by 2,572.2% in the 3rd quarter. Rehmann Capital Advisory Group now owns 26,188 shares of the real estate investment trust’s stock valued at $995,000 after buying an additional 25,208 shares during the period. 90.00% of the stock is owned by institutional investors.
Several research analysts recently weighed in on the stock. Zacks Investment Research restated a “sell” rating on shares of HCP in a research report on Tuesday, November 13th. ValuEngine upgraded shares of HCP from a “hold” rating to a “buy” rating in a research report on Monday, November 12th. Royal Bank of Canada upgraded shares of HCP from a “sector perform” rating to an “outperform” rating in a research report on Friday, November 2nd. Cantor Fitzgerald upped their price objective on shares of HCP from $29.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 1st. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $27.00 price objective on shares of HCP in a research note on Wednesday, October 31st. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company’s stock. HCP has a consensus rating of “Hold” and an average price target of $26.75.
TRADEMARK VIOLATION NOTICE: “HCP, Inc. (HCP) COO Thomas Klaritch Sells 82,532 Shares” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/12/07/hcp-inc-hcp-coo-thomas-klaritch-sells-82532-shares.html.
HCP Company Profile
HCP, Inc is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.
Featured Story: How interest rates affect municipal bond prices
Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.